Lower levels of LDL cholesterol, as well as the duration of low LDL, are important for the prevention and management of atherosclerotic cardiovascular disease (ASCVD), according to James Underberg, MS, MD,...
It is important to differentiate between apparent and true resistant hypertension, a discrimination that Robert D Brook, MD will discuss further in his presentation, “Management of Resistant Hypertension.”
...
Although HDL cholesterol is consistently associated with higher cardiovascular risk, the targeting of HDL has not meaningfully improved outcomes, according to Amit Khera, MD, MSc, FACC, FAHA, FASPC, who...
In The Role of SGLT-2 Inhibitors in the Management of T2DM," Anne L Peters, MD, details treatment with empagliflozin and canagliflozin and its effects on outcomes including blood pressure, CV death,...
Deborah Bade Horn, DO, MPH, FOMA, will present “How to Help Your Patients Lead a Physically Active Life” today at the Cardiometabolic Risk Summit. In her presentation, she will discuss how to best prescribe...
The ACA and the AHA developed Appropriate Use Criteria for the treatment of patients with severe aortic stenosis, including 95 clinical scenarios and 6 potential treatment options.